The care process of patient receiving car ...
Type de document :
Article dans une revue scientifique: Article de synthèse/Review paper
PMID :
URL permanente :
Titre :
The care process of patient receiving car t-cell therapy: guidelines from the francophone society of bone marrow transplantation and cellular therapy (sfgm-tc)
Auteur(s) :
Beauvais, David [Auteur]
Andrianne, Christelle [Auteur]
Aubrun, Clotilde [Auteur]
Berquier, Maxime [Auteur]
Bole, Sarah [Auteur]
Caulier, Alexis [Auteur]
Courbon, Corinne [Auteur]
Delorme, Josiane [Auteur]
FOURNIER, Isabelle [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Francois, Ghislaine [Auteur]
Jaivenois, Marie-France [Auteur]
Le Bars, Laetitia [Auteur]
Mussot, Isabelle [Auteur]
Vercasson, Marlene [Auteur]
Wallart Brejaud, Anne [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lacroix, Damien [Auteur]
Andrianne, Christelle [Auteur]
Aubrun, Clotilde [Auteur]
Berquier, Maxime [Auteur]
Bole, Sarah [Auteur]
Caulier, Alexis [Auteur]
Courbon, Corinne [Auteur]
Delorme, Josiane [Auteur]
FOURNIER, Isabelle [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Francois, Ghislaine [Auteur]
Jaivenois, Marie-France [Auteur]
Le Bars, Laetitia [Auteur]
Mussot, Isabelle [Auteur]
Vercasson, Marlene [Auteur]
Wallart Brejaud, Anne [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lacroix, Damien [Auteur]
Titre de la revue :
Bulletin du cancer
Nom court de la revue :
Bull Cancer
Date de publication :
2020-09-02
ISSN :
1769-6917
Mot(s)-clé(s) :
Coordinating nurse
Care process
CAR T-cell
Care process
CAR T-cell
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. While these treatments are available for use, allogeneic hematopoietic stem cell transplantation ...
Lire la suite >In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. While these treatments are available for use, allogeneic hematopoietic stem cell transplantation centers still need to set up a dedicated care process inspired by established procedures in the field. In order to determine necessary resources and actors, each step of the CAR T-cell care process must be planned in advance. This process, implemented by the center's coordinating nurse, should be able to be adapted to each center's needs. The purpose of this workshop is to provide the organizational basis for such a process so that each center wishing to set up CAR-T cell activity can do so effectively. After detailing the coordinating nurse's role, we explain each step of the care process and specify essential additional tests.Lire moins >
Lire la suite >In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. While these treatments are available for use, allogeneic hematopoietic stem cell transplantation centers still need to set up a dedicated care process inspired by established procedures in the field. In order to determine necessary resources and actors, each step of the CAR T-cell care process must be planned in advance. This process, implemented by the center's coordinating nurse, should be able to be adapted to each center's needs. The purpose of this workshop is to provide the organizational basis for such a process so that each center wishing to set up CAR-T cell activity can do so effectively. After detailing the coordinating nurse's role, we explain each step of the care process and specify essential additional tests.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
INSERM
Université de Lille
Université de Lille
Collections :
Date de dépôt :
2021-07-06T12:48:51Z